ARRIS - Another partner Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARRIS - Another partner

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: TomOrt who wrote (267)	12/2/1997 1:34:00 PM
From: John Dwyer	Read Replies (2) of 353

Well, the cat's out of the bag... This is a good idea but they are still vague... a fact that has dampened my enthusiasm for Delta from day one. My guess is that they are using the catalytic His-Ser to coordinate a metal ion. The rest of the coordination comes from the Delta scaffold I would guess. They must be able to build out from this into the specificity pocket to make drugs specific for a particular protease. This gives the specificity and the metal binding, which would be similar for all serine proteases, gives the compound a much stronger binding energy (makes it more potent). One could also use a small version of Delta and screen using standard methods (phage display, etc.) to discover non-active site inhibs. If the inhib binds near the active site, then you could couple the two together somehow. This is interesting and I look forward to the scientific report, but I still feel that this is not really living up to all the hype that has been placed on Delta. John

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next